MAP3K14 and Hodgkins lymphoma: Some in vitro studies have shown promising results with NIK inhibition in Hodgkin lymphoma (66) and mantle cell lymphoma (MCL) (49), yet these studies did apply inhibitors designed before publication of the crystal structure of NIK in 2012 (12, 13).